インターフェロンの世界市場：現状分析と予測（2022年～2028年）

世界のインターフェロンの市場規模は、予測期間中に約4％の大幅な成長が予測されています。

当レポートでは、世界のインターフェロン市場について調査分析し、市場規模と予測分析、主な動向と機会、企業プロファイルなどの情報を提供しています。

目次

第1章 市場のイントロダクション

第2章 調査手法・前提条件

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 インターフェロン市場に対するCOVID-19の影響

第6章 インターフェロン市場の収益（2020年～2028年）

第7章 市場の考察：製品別

• インターフェロンガンマ
• インターフェロンベータ
• インターフェロンアルファ

第8章 市場の考察：適応症別

• 多発性硬化症
• 真性赤血球増加症
• C型肝炎
• メラノーマ
• 慢性肉芽腫症（CGD）
• その他

第9章 市場の考察：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第10章 市場の考察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他の地域

第11章 インターフェロンの市場力学

• 市場促進要因
• 市場の課題
• 影響の分析

第12章 インターフェロン市場の機会

第13章 インターフェロン市場の動向

第14章 デマンドサイドとサプライサイドの分析

• デマンドサイド分析
• サプライサイド分析

第15章 バリューチェーン分析

第16章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第17章 企業プロファイル

• Roche
• Merck & Co.
• Bristol-Myers Squibb
• Biogen Inc.
• Bayer AG
• Zydus Cadila
• Novartis AG
• Pfizer Inc.
• Biosidus
• Synairgen

第18章 免責事項

The global interferons market is expected to grow at a significant rate of around 4% during the forecast period. Interferons are an important protein of the immune system that is produced by white blood cells. Furthermore, the interferons are the natural defense against viral infection, bacterial infections, cancer, and other diseases. However, interferon can also be artificially synthesized which is used in the treatment of a number of diseases. Furthermore, the number of diseases that are responsible for rising cases of immunocompromisation in the population rises the demand for interferons. For instance, as per hiv.gov, there were approximately 38.4 million people across the globe with HIV in 2020. Of these, 36.7 million were adults and 1.7 million were children (<15 years old). In addition, 54% were women and girls

Roche, Merck & Co., Bristol-Myers Squibb, Biogen Inc., Bayer AG, Zydus Cadila, Novartis AG, Pfizer Inc., Biosidus, and Synairgen are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst product, interferon beta category to witness higher CAGR during the forecast period"

Based on the product, the market has been categorized into interferon gamma, interferon beta, and interferon alpha. The interferon-beta category is to witness a higher CAGR during the forecast period owing to its efficacy in the treatment of various brain disorders such as hepatitis. Additionally, the interferon beta also helps to reduce the episodes of relapsing-remitting which is a symptom of multiple sclerosis.

"Amongst indication, multiple sclerosis to hold a significant share in the market in 2020"

Based on the indication, the market has been categorized into multiple sclerosis, polycythemia vera, hepatitis c, melanoma, chronic granulomatous disease (CGD), and others. Among these, multiple sclerosis to hold a significant share of the market in 2020. Interferon treatment showed an impressive result in the treatment of multiple sclerosis is the one of main reasons for the rising demand for interferon in multiple sclerosis treatment. The higher number of multiple sclerosis incidences is an important factor for the growth of the interferon market. For instance, as per the National MS Society, in 2019, nearly one million people are living with multiple sclerosis in the United States.

"Amongst distribution channels, the hospital pharmacies to hold a significant share in the market in 2020"

Based on the distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others. Among these, hospital pharmacies to hold a significant share of the market in 2020. Hospital pharmacies represent one of the most lucrative options for patients for the consumables of drugs. Apart from this, several physicians require the presence of a trained physician and are therefore expected to drive segmental growth.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the interferons industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. In 2020, North America held a significant share of the global Interferons market. This is mainly attributed to the rising number of product launches and the increasing healthcare investments in the region. For instance, in November 2021, PharmaEssentia Corporation announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera (PV). Furthermore, the rising geriatric population in the region is also an important factor that increases the market size of interferons in North America.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global interferons market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Interferons Market
• 2.2. Research Methodology of the Interferons Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE INTERFERONS MARKET

6 INTERFERONS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY PRODUCT

• 7.1. Interferon Gamma
• 7.2. Interferon Beta
• 7.3. Interferon Alpha

8 MARKET INSIGHTS BY INDICATION

• 8.1. Multiple Sclerosis
• 8.2. Polycythemia Vera
• 8.3. Hepatitis C
• 8.4. Melanoma
• 8.5. Chronic Granulomatous Disease (CGD)
• 8.6. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 INTERFERONS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 INTERFERONS MARKET OPPORTUNITIES

13 INTERFERONS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. Roche
• 17.2. Merck & Co.
• 17.3. Bristol-Myers Squibb
• 17.4. Biogen Inc.
• 17.5. Bayer AG
• 17.6. Zydus Cadila
• 17.7. Novartis AG
• 17.8. Pfizer Inc.
• 17.9. Biosidus
• 17.10. Synairgen

18 DISCLAIMER